BDKRB1 and ovarian cancer: Pharmacogenomic analyses suggested distinct drug sensitivity patterns in BDKRB1-high tumors and identified fasudil as a potential candidate compound for reversing BDKRB1-associated transcriptional signatures.<h4>Conclusion</h4>This integrative analysis identifies BDKRB1 as a microenvironment-associated marker linking genomic instability with inflammatory and immunosuppressive tumor ecosystems in ovarian cancer.